DAMORA THERAPEUTICS, INC. Operating Expenses
DAMORA THERAPEUTICS, INC. (DMRA) reported Operating Expenses of $34.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $34.99M, a 922.92% increase year-over-year.
- DAMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $30.81M, a 1085.49% increase year-over-year.
- DAMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $201.70M, a 2739.99% increase year-over-year.
- DAMORA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $3.16M, a 17.81% decline year-over-year.
- DAMORA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $210.87M, a 847.31% increase from fiscal 2024.
- DAMORA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $22.26M, a 44.22% decline from fiscal 2023.
- DAMORA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $39.91M, a 34.80% decline from fiscal 2022.
- DAMORA THERAPEUTICS, INC. operating expenses for fiscal 2022 was $61.21M, a 17.19% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.99M 10-Q · filed 2026-08-10 | $65.81M 10-Q · filed 2026-08-10 | $267.50M derived: sum of 3 quarters · filed 2026-08-10 | $270.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $30.81M 10-Q · filed 2026-05-12 | $232.51M derived: sum of 2 quarters · filed 2026-05-12 | $235.66M derived: sum of 3 quarters · filed 2026-05-12 | $239.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $201.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $204.85M derived: sum of 2 quarters · filed 2026-03-19 | $208.27M derived: sum of 3 quarters · filed 2026-08-10 | $210.87M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.16M 10-Q · filed 2025-11-06 | $6.58M derived: sum of 2 quarters · filed 2026-08-10 | $9.18M 10-Q · filed 2025-11-06 | $16.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $3.42M 10-Q · filed 2026-08-10 | $6.02M 10-Q · filed 2026-08-10 | $13.12M derived: sum of 3 quarters · filed 2026-08-10 | $16.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-12 | $9.70M derived: sum of 2 quarters · filed 2026-05-12 | $13.54M derived: sum of 3 quarters · filed 2026-05-12 | $19.12M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.94M derived: sum of 2 quarters · filed 2026-03-19 | $16.52M derived: sum of 3 quarters · filed 2026-03-19 | $22.26M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.84M 10-Q · filed 2025-11-06 | $9.42M derived: sum of 2 quarters · filed 2025-11-06 | $15.16M 10-Q · filed 2025-11-06 | $21.83M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.58M 10-Q · filed 2025-08-05 | $11.32M 10-Q · filed 2025-08-05 | $17.99M derived: sum of 3 quarters · filed 2025-08-05 | $26.57M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $5.74M 10-Q · filed 2025-05-08 | $12.41M derived: sum of 2 quarters · filed 2025-05-08 | $21.00M derived: sum of 3 quarters · filed 2025-05-08 | $32.15M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $15.25M derived: sum of 2 quarters · filed 2025-03-19 | $26.41M derived: sum of 3 quarters · filed 2025-03-19 | $39.91M 10-K · filed 2025-03-19 |
| 2023-09-30 | $8.58M 10-Q · filed 2024-11-01 | $19.74M derived: sum of 2 quarters · filed 2024-11-01 | $33.23M 10-Q · filed 2024-11-01 | $46.76M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $11.16M 10-Q · filed 2024-08-12 | $24.65M 10-Q · filed 2024-08-12 | $38.18M derived: sum of 3 quarters · filed 2024-08-12 | $51.80M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $13.49M 10-Q · filed 2024-04-29 | $27.02M derived: sum of 2 quarters · filed 2024-04-29 | $40.64M derived: sum of 3 quarters · filed 2024-04-29 | $57.76M derived: sum of 4 quarters · filed 2024-04-29 |
| 2022-12-31 | $13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $27.15M derived: sum of 2 quarters · filed 2024-03-08 | $44.27M derived: sum of 3 quarters · filed 2024-03-08 | $61.21M 10-K · filed 2024-03-08 |
| 2022-09-30 | $13.62M 10-Q · filed 2023-11-06 | $30.74M derived: sum of 2 quarters · filed 2023-11-06 | $47.68M 10-Q · filed 2023-11-06 | $61.15M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $17.12M 10-Q · filed 2023-07-31 | $34.06M 10-Q · filed 2023-07-31 | $47.53M derived: sum of 3 quarters · filed 2023-07-31 | $60.47M derived: sum of 4 quarters · filed 2023-07-31 |
| 2022-03-31 | $16.94M 10-Q · filed 2023-04-28 | $30.41M derived: sum of 2 quarters · filed 2023-04-28 | $43.35M derived: sum of 3 quarters · filed 2023-04-28 | $55.61M derived: sum of 4 quarters · filed 2023-04-28 |
| 2021-12-31 | $13.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $26.41M derived: sum of 2 quarters · filed 2023-03-09 | $38.67M derived: sum of 3 quarters · filed 2023-03-09 | $52.23M 10-K · filed 2023-03-09 |
| 2021-09-30 | $12.94M 10-Q · filed 2022-11-08 | $25.21M derived: sum of 2 quarters · filed 2022-11-08 | $38.76M 10-Q · filed 2022-11-08 | $50.06M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $12.27M 10-Q · filed 2022-07-29 | $25.82M 10-Q · filed 2022-07-29 | $37.12M derived: sum of 3 quarters · filed 2022-07-29 | $47.29M derived: sum of 4 quarters · filed 2022-07-29 |
| 2021-03-31 | $13.55M 10-Q · filed 2022-04-29 | $24.85M derived: sum of 2 quarters · filed 2022-04-29 | $35.02M derived: sum of 3 quarters · filed 2022-04-29 | $41.36M derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | $11.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $21.47M derived: sum of 2 quarters · filed 2022-02-17 | $27.81M derived: sum of 3 quarters · filed 2022-02-17 | $33.64M 10-K · filed 2022-02-17 |
| 2020-09-30 | $10.17M 10-Q · filed 2021-11-04 | $16.50M derived: sum of 2 quarters · filed 2021-11-04 | $22.34M 10-Q · filed 2021-11-04 | $47.19M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $6.34M 10-Q · filed 2021-08-05 | $12.17M 10-Q · filed 2021-08-05 | $37.02M derived: sum of 3 quarters · filed 2021-08-05 | $41.85M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $5.83M 10-Q · filed 2021-05-04 | $30.68M derived: sum of 2 quarters · filed 2021-05-04 | $35.51M derived: sum of 3 quarters · filed 2021-05-04 | |
| 2019-12-31 | $24.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $29.68M derived: sum of 2 quarters · filed 2021-03-29 | $38.97M 10-K · filed 2021-03-29 | |
| 2019-09-30 | $4.83M 10-Q · filed 2020-12-11 | $14.12M 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |